Skip to main content

Table 3 Primers for Pol and LTR amplification and sequencing

From: The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa

Amplification primers

Primer Number

Description

Co-ordinates (HXB2) /Length

Sequence (5'–3')

Product length

Protease

 N1636

EFP

1978–2006, 29

AAGGAAGGGCACCCAGCCAGAAATTGCAG

864

 N1637

ERP

2813–2842, 30

GCGGGATGTGGTATCCCTAATTGAACTTCC

 N1638

IFP

2075–2103, 29

GACAGGCTAATTTTTTAGGGAARATTTGG

530

 N1639

IRP

2577–2605, 29

GGGCCATCCATTCCTGGCTTTAATTTTAC

RT

 N1641

EFP

2368–2395, 28

CAGGAAGATGGAAACCAAAAATGATAGG

2114

 N1642

ERP

4455–4482, 28

CTATATATCCACTGGCTACATGAACTGC

 N1643

IFP

2489–2509, 21

TACACCTGTCAACATAATTGG

1816

 N1644

IRP

4285–4305, 21

AATCACTAGCCATTGCTCTCC

RNaseH/Integrase

 N2244

EFP

3628–3660, 33

CCCACACTAATGATGTAAAACAGTTAACAGAGG

1659

 N2245

ERP

5257–5287, 31

CCATGACCCAAATGCCAATCTCTTTCTCCTG

 N2246

IFP

3738–3765, 28

ATGGGAAACATGGTGGACAGACTATTGG

1476

 N2247

IRP

5185–5214, 30

TGGGATGTGTACTTCTGAACTTAYTTTTGG

LTR

 N698

EFP

1–34, 34

TGGAAGGGTTAATTTACTCYMAGAAAAGRCAAGA

555

 N1032

ERP

538–556, 19

TAGAGCACGCAAGGCAAGC

 N558

IFP

1–43, 43

TGGAAGGGTTAATTTACTCTAAGGAAAGGCAAGAGATCCTTG

431

 N1204

IRP

411–432, 21

CTTATATGCAGGATCTGAGGG

Sequencing primers

gene

 N1645

Forward Primers

2620–2635, 16

GGCCATTGACAGAAGA

RT

 N1646

3108–3124, 17

TTGTATGTAGGATCTGA

 N1647

3626–3642, 17

TGCCCACACTAATGATG

 N1648

Reverse primers

3870–3886, 17

GCTGCCCCATCTACATA

 N1649

3345–3362, 18

GTAAATCTGACTTGCCCA

 N1650

2889–2906, 18

GGGAACTGAAAAATATGC

 9 M

Forward Primers

4145–4167, 21

CCTGTCATGGGTACCAGCACA

RNaseH/Integrase

 10 M

4664–4687, 24

CCAAAGTCAGGGAGTAGTAGAATC

 28 M

Reverse primers

4957–4978, 22

ACTACTGCCCCTTCACCTTTCC

 29 M

4380–4401, 22

GACTGCAGTCTACTTGTCCATG

  1. Protease and LTR were sequenced using amplification primers